MIS-C Treatment: Is IVIG Always Necessary?

• DOI: 10.3389/fped.2021.753123
• Publication Date: 2021-11-03T07:18:56Z
• Authors: Francesco Licciardi; Letizia Baldini; Marta Dellepiane; Carlotta Covizzi; Roberta Mogni; Giulia Pruccoli; Cecilia Orsi; Ivana Rabbone; Emilia Parodi; Federica Mignone; Davide Montin
• Keywords: Intravenous Immunoglobulins

Background: MIS-C is a potentially severe inflammatory syndrome associated with SARS-CoV-2 exposure. Intravenous immunoglobulin (IVIG) considered the first-tier therapy, but it implies infusion of large fluid volumes that may worsen cardiac function. Patients and Methods: Since April 2020, we have developed treatment protocol avoids IVIG as first-line therapy in early phase MIS-C. In this study, retrospectively analyzed cohort consecutive patients treated according to between 01/04/2020 01/04/2021. Results: last year, 31 been protocol: 25 high-dose pulse MP (10 mg/kg) 6 2 mg/kg. 67.7% responded initial treatment, while others needed step-up, either Anakinra (25.8%) or dose increase (6.5%). was administered four patients. Overall, only one patient (3.2%) ICU admission inotropic support; small coronary artery aneurysm. Conclusions: Timely start careful management might improve outcomes